Ixekizumab (anti-IL-17A) is a biologic medication used to treat moderate-to-severe psoriasis. There is currently a scarcity of real-world evidence on the efficacy and safety of ixekizumab. The goal of this research was to assess the efficacy and safety of ixekizumab in a group of psoriatic and psoriatic arthritis patients. A retrospective research including 201 individuals with moderate-to-severe psoriasis who were treated with ixekizumab at seven Italian university centres was undertaken. The study looked at 110 individuals who started ixekizumab from the beginning and finished at least 24 weeks of therapy. At 4 weeks of ixekizumab treatment, there was a substantial reduction in mean baseline Psoriasis Area Severity Index (PASI) score, with additional significant improvement at weeks 12 and 24. After 24 weeks of therapy, 90 percent, 72 percent, and 57 percent of patients achieved PASI 75, 90, and 100 responses, respectively. A substantial reduction in the mean baseline Disease Activity Score (DAS)-28 score was seen in individuals with arthritis at week 4, with subsequent significant improvements at weeks 12 and 24. At week 12, the bio-naive group had substantially higher PASI 90 and 100 reaction rates than the bio-exposed group.

In terms of PASI 100 reaction, this pattern was likewise maintained at week 24. Furthermore, at week 24, PASI 90 responses were substantially greater in anti-interleukin (IL)-17A-naive patients compared to anti-IL-17A-experienced patients. The dropout rate for adverse events (AEs) was as low as 2%, with AEs that did not require treatment discontinuation occurring in 6% of cases. According to the non-responder imputation technique, patients who dropped out of the trial were classified as non-responders. The study’s retrospective methodology prevents the retrieval of missing data or the use of homogenous patient selection.

Reference:https://link.springer.com/article/10.1007/s40257-019-00490-2